Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXELDERM vs GYNIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.
Coagulative necrosis of tissue via trichloroacetic acid; chemical cauterization of epithelial cells.
Tinea pedis,Tinea cruris,Tinea corporis,Tinea versicolor
Cervical inflammation,Vaginal infections,Treatment of genital warts,Chemical cautery of skin lesions
Apply a thin layer to affected skin twice daily (morning and evening).
1 vaginal tablet (100 mg) once daily at bedtime for 7 days
Not applicable due to negligible systemic absorption; after topical application, half-life in skin is several hours.
Terminal half-life is 2.5-3 hours in patients with normal renal function; prolonged to 6-8 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 12-15 hours in severe renal impairment (Cr Cl <30 m L/min).
Minimal systemic absorption; when absorbed, primarily metabolized in the liver via oxidation and glucuronidation.
Not metabolized; acts locally via direct chemical action.
Systemic absorption is minimal; any absorbed sulconazole is primarily metabolized in the liver and excreted in feces via bile; renal excretion of unchanged drug is negligible.
Primarily renal (approximately 60-80% as unchanged drug) and biliary (20-30% as metabolites; unchanged drug not detected in bile). Fecal elimination accounts for <5%.
Not applicable; systemic levels are undetectable with topical use.
Approximately 20-30% bound to albumin with negligible binding to alpha-1-acid glycoprotein.
Not applicable; negligible systemic absorption.
Apparent Vd is 0.8-1.1 L/kg (range 0.6-1.3 L/kg), indicating extensive tissue distribution (e.g., lung, liver, bone).
Topical: negligible systemic bioavailability (<1%) due to poor percutaneous absorption.
Oral: 85-95% (immediate-release) and 70-80% (sustained-release due to first-pass effect). Vaginal: 5-10% (minimal systemic absorption). IV: 100%.
No dosage adjustment required for renal impairment.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min: use with caution, consider alternative therapy.
No dosage adjustment required for hepatic impairment.
Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe (Child-Pugh C): contraindicated.
Safety and efficacy in pediatric patients below 12 years have not been established; see prescribing information for age-specific recommendations.
Not approved for use in pediatric patients.
No specific geriatric dose adjustments; use caution due to higher risk of adverse effects from prolonged use.
No dose adjustment required; use same as adult dosing.
None.
None.
Avoid contact with eyes, nose, mouth, or other mucous membranes. Discontinue if irritation or sensitization occurs. Not for oral or ophthalmic use. Use in children under 12 years not established.
Avoid contact with normal tissue; risk of chemical burns; not for use on neoplastic lesions.
Known hypersensitivity to sulconazole or any component of the formulation.
Hypersensitivity to trichloroacetic acid; pregnancy (relative); use on malignant tissue.
None known.
No known food interactions with topical use. However, avoid concurrent use of iodine-containing supplements or medications, as it may increase systemic iodine load.
Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.
First trimester: Inadequate human data; animal studies not available. Theoretical risk based on pharmacologic action. Second and third trimesters: No known fetal harm from topical use. Systemic absorption minimal.
Not known if excreted in breast milk. Caution in nursing mothers; limited data. M/P ratio not available.
No data on excretion in human milk. Expected minimal systemic absorption. Use caution if applied to breast area. M/P ratio unknown.
No dose adjustment required for topical use; insufficient data for systemic absorption changes.
No dose adjustment necessary for topical use. Systemic absorption negligible.
Apply sparingly to affected area; avoid use on mucous membranes or intertriginous areas. Discontinue if irritation occurs. Not recommended for use under occlusive dressings.
GYNIX (povidone-iodine) is a topical antiseptic. Avoid use in patients with iodine hypersensitivity or thyroid disorders (e.g., Hashimoto's thyroiditis). Prolonged use on large wounds may cause iodine absorption and thyroid dysfunction. Monitor for local irritation or allergic contact dermatitis.
Use only on the skin as directed; avoid contact with eyes, mouth, or open wounds.,Wash hands before and after applying unless treating hands.,Do not cover the treated area with bandages or wrappings unless directed by a doctor.,Stop use and consult doctor if condition worsens or does not improve within 2 weeks.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Do not use if you are allergic to iodine or have a thyroid condition.,For external use only. Avoid contact with eyes, mouth, or open wounds unless directed.,Discontinue and inform your doctor if you develop rash, itching, or swelling.,Store at room temperature away from light. Do not freeze or heat.,Not for use on deep or puncture wounds, or severe burns without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXELDERM vs GYNIX, answered by our medical review team.
EXELDERM is a Topical Antifungal that works by Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.. GYNIX is a Polyene Antifungal that works by Coagulative necrosis of tissue via trichloroacetic acid; chemical cauterization of epithelial cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXELDERM and GYNIX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXELDERM is: Apply a thin layer to affected skin twice daily (morning and evening).. The standard adult dose of GYNIX is: 1 vaginal tablet (100 mg) once daily at bedtime for 7 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXELDERM and GYNIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXELDERM is classified as Category C. Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.. GYNIX is classified as Category C. First trimester: Inadequate human data; animal studies not available. Theoretical risk based on pharmacologic action. Second and third trimesters: No known fetal harm from topical . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.